Global

Search

Filter by category
Filter by category
reset filters
diagram of lungs and inhaler

How Might Choice of Salbutamol Metered Dose Inhaler (MDI) Type and Use of a Spacer Impact Drug Delivery and Emissions - Best for the Patient and Environment

As current MDIs contain hydrofluorocarbon propellants, it would be beneficial to find ways to reduce carbon emissions without compromising patient safety.

This lab study investigated a way to optimize the modelled lung dose per actuation while at the same time minimizing the carbon emissions from the MDI

View details

AEROLIV* App: Asthma + COPD Mentor

Stress less symptom control 
View details
lifestyle doctor and patient

Inspiratory Profiles from Volunteer Adults who Have Read the Patient Instructions for Use for Two Passive Dry Powder Inhalers (DPIs) Compared with those from a Pressurized Metered Dose Inhaler with Valved Holding Chamber (pMDI+VHC)

This study was presented at the Drug Delivery to the Lungs, 2022.

View details
Using Functional Respiratory Imaging

Using Functional Respiratory Imaging (FRI) to Compare Predicted Airway Deposition Between Pressurized Metered Dose Inhaler (pMDI) with AeroChamber Plus* Flow-Vu* Valved Holding Chamber (VHC) and Two Dry Powder Inhalers (DPIs) in a COPD patient

This study was presented at the Drug Delivery to the Lungs Conference, 2022.

View details
reduce your carbon footprint

Maximizing the benefit from the inhaler in order to minimize carbon footprint.

Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.

In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.

By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.

View details
reduce your carbon footprint

Maximizing the benefit from the inhaler in order to minimize carbon footprint

Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.

In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.

By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.

View details

Living with NTM Lung Disease

Nontuberculous mycobacterial (NTM) lung disease is a chronic, progressive condition caused by nontuberculous mycobacteria. NTM lung disease occurs more frequently in older adults and people with other lung diseases, like bronchiectasis, and chronic obstructive pulmonary disease (COPD).

View details

Living with Bronchiectasis

Bronchiectasis is a chronic, progressive lung condition affecting infants, children and adults. While the global prevalence of bronchiectasis is not accurately known,1 there is a growing awareness of the disease.2

View details

Living with Asthma

Asthma is a chronic respiratory disease, characterized by narrowing of the airways and excess mucus production. People with asthma typically suffer from chest tightness/pain, shortness of breath, and episodes of coughing and wheezing.

View details

Living with Cystic Fibrosis

Cystic fibrosis (CF) is a progressive, genetic condition affecting more than 100,000 people worldwide.1 There are over 4,300 people living with CF in Canada.2

View details

What is an Asthma Attack?

View details

Living with COPD

Chronic Obstructive Pulmonary Disease (COPD) affects around 251 million people globally.1 It is a term that covers two types of chronic (long-term) diseases where the airways in the lungs become “obstructed” or partly blocked.

View details